2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS-News: M1 Kliniken AG
/ Key word(s): Personnel
Expansion of the Management Board of M1 Kliniken AG Berlin, 24.11.2022 - The Supervisory Board of M1 Kliniken AG today appointed Mr. Attila Strauss to the Management Board of M1 Kliniken AG with immediate effect. Mr. Strauss has already been a member of the Management Board of HAEMATO AG since April 1, 2022 and has contributed to a significant cost reduction and efficiency increase there in a short period of time. Dr. von Horstig is leaving the company and will in future devote himself to new challenges outside the M1 group of companies. The Supervisory Board would like to thank Dr. von Horstig for his more than five years of responsible service as a member of the Management Board, during which time the company was expanded to its current importance. Mr. Kilian Brenske, further member of the Management Board of M1 Kliniken AG: "I look forward to working with Mr. Strauss, who brings extensive knowledge and experience in the area of digitalization and cost reduction measures, to further drive the efficiency increase (margin improvement) and internationalization of the company and thus further expand our position as a leading provider of beauty medicine." About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 50 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia, Hungary and Australia. With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
24.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1496673 |
| End of News | EQS News Service |
|
|
1496673 24.11.2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
